Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.

Computational and structural biotechnology journal·2026
Same author

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.

Cancer research communications·2026
Same author

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Journal of the National Cancer Institute·2026
Same author

Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation.

Cancers·2026
Same author

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Neuro-oncology advances·2026
Same author

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Science advances·2026

相关实验视频

Updated: May 5, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

基于抗PD-L1的RCT后的第二事件终点 (EFS2,PRFS2和PFS2):系统性审查和元分析.

Pablo Jimenez-Labaig1,2,3, Oriol Mirallas3,4,5, Ana Isabel Martin-Quesada6,7

  • 1Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK pablojimenez.pjl@gmail.com.

Journal for immunotherapy of cancer
|November 28, 2025
PubMed
概括

早期使用抗PD-(L) 1免疫疗法显著改善了固体瘤的长期结果. 无事件生存率2 (EFS2),无进展/无复发生存率2 (PRFS2) 和无进展生存率2 (PFS2) 是整体生存率 (OS) 的强有力的替代品.

关键词:
免疫检查点抑制剂 免疫检查点抑制剂免疫治疗是一种免疫疗法.固体瘤是一个固体瘤.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

相关实验视频

Last Updated: May 5, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.6K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 临床试验 临床试验

背景情况:

  • 免疫检查点抑制剂 (ICI),特别是抗PD-(L) 1疗法,已经彻底改变了癌症治疗.
  • 与传统的第一事件指标相比,EFS2,PRFS2和PFS2等新型终点可以更准确地评估持久的临床益处.
  • 本研究评估了早期使用抗PD-(L) 1药物的影响以及这些长期终点在固体瘤中的有效性.

研究的目的:

  • 审查早期抗PD-(L) 1治疗在固体恶性瘤中所带来的益处的大小.
  • 评估长期终点 (EFS2,PRFS2,PFS2) 作为癌症免疫治疗中整体存活 (OS) 的可靠替代品.
  • 根据免疫疗法疗效的临床决策和监管评估提供信息.

主要方法:

  • 在实体瘤中对基于抗PD-(L) 1的随机对照试验 (RCT) 进行了系统审查和元分析.
  • 分析了47个RCT (34,973名患者) 的数据,重点关注EFS2,PRFS2,PFS2和OS.
  • 统计分析包括随机效应元分析和线性回归来比较终点相关性.

主要成果:

  • 早期抗PD-(L) 1使用显著改善EFS2/PRFS2/PFS2 (HR 0.72),在不同环境和瘤类型 (例如NSCLC,MSI高) 中具有一致的益处.
  • EFS2/PRFS2/PFS2与OS有很强的相关性 (总体R2=0.74,NSCLC中的R2=0.86),表现优于传统的PFS/DFS (总体R2=0.39,NSCLC中的R2=0.65).
  • 在非ICI经验丰富的患者中,抗PD-(L) 1s作为后续治疗的有效性降低.

结论:

  • 早期使用抗PD-(L) 1疗法可以延长疾病的控制时间,并可能提高后续治疗反应.
  • 在免疫疗法试验中,EFS2,PRFS2和PFS2被验证为OS的强大的替代品.
  • 这些长期终点应该经常纳入免疫疗法RCT,以更好地捕捉持久的益处.